Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST. A separate Scientific Exhibit of STEDESA data will be held on Monday, December 7, 2009 from 8:00 am to 5:00 pm EST at the Sheraton Boston Hotel in Ballroom C and will include the posters presented during the poster session as well as additional posters of pharmacokinetic, safety and efficacy data and design posters for two ongoing trials.
Saturday, December 5, 2009 Poster Session:
- An Investigation of the Effects of Eslicarbazepine Acetate on Hyponatremia: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies
- An Investigation of the Effect of Eslicarbazepine Acetate on Cardiac Repolarization: A Pooled Analysis of Over-Read Electrocardiograms From Three Double-Blind Phase III Clinical Studies
- An Evaluation of the Effect of Eslicarbazepine Acetate on Metabolic Parameters: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies
- An Evaluation of Depressive Symptoms Following Treatment With Eslicarbazepine Acetate: A Pooled Analysis in the Open-Label Extensions of Three Phase III Studies in Subjects With Partial-Onset Seizures
- Incidence of Rash in the Pooled Population of Three Placebo-Controlled Phase III Clinical Trials With Eslicarbazepine Acetate
- An Investigation of the Therapeutic Effect of Eslicarbazepine Acetate Combined With Carbamazepine: Pooled Analysis of Three Placebo-Controlled Phase III Clinical Studies
- An Investigation of the Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Carbamazepine: A Pooled Analysis of the Three Placebo-Controlled Phase III Clinical Studies
Monday, December 7, 2009 Scientific Exhibit: